Novadien (Dienogest, Ethinylestradiol)

The combination of dienogest (a progestogen) and ethinylestradiol (an estrogen) suppresses the hypothalamic‑pituitary‑ovarian axis, reducing LH and FSH secretion and thereby preventing ovulation. It also thickens cervical mucus and alters the endometrium, creating conditions that are unfavorable for sperm penetration and implantation.

The dosing regimen for Novadien is determined by the prescribing healthcare professional. Typically, the product is taken as one oral tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are set by the prescriber.

Novadien is not intended for use during pregnancy; if pregnancy occurs, the tablet should be discontinued and alternative care considered. Safety data for breastfeeding are limited, and clinicians usually advise caution, recommending that women discuss potential risks and benefits with their healthcare provider.

To order Novadien, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Novadien contains dienogest, a progestogen with a slightly higher anti‑androgenic profile, combined with ethinylestradiol. Compared with other COCs that use levonorgestrel or desogestrel, Novadien may offer different bleeding patterns and a distinct side‑effect profile, but overall contraceptive efficacy remains comparable when taken as directed.

Novadien tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight and heat sources to maintain stability and potency throughout its shelf life.

Novadien is taken orally, usually as one tablet each day at the same time. The tablet is swallowed whole with water and should be started on the first day of the menstrual cycle or as directed by a healthcare professional.

Serious risks include thromboembolic events such as deep vein thrombosis, pulmonary embolism, stroke, and myocardial infarction. Rare but severe allergic reactions and significant liver dysfunction have also been reported. Patients should seek immediate medical attention if they experience symptoms like sudden leg pain, shortness of breath, chest pain, severe headache, or jaundice.

Novadien is contraindicated in women with a history of thromboembolic disorders, uncontrolled hypertension, known or suspected breast cancer, active liver disease, or those who are pregnant. It should also be avoided by smokers over 35 years of age and by individuals taking medications that strongly induce CYP3A4 enzymes without appropriate contraceptive backup.